

Press release Sangair, 7 Mars 2024

Sangair patent is approved in Canada

The intellectual property family has expanded with an approved patent application in Canada, pertaining to ozonation of blood, and more countries are in pipeline the upcoming years.

Sangair now have IP that covers the whole north American region.

About Sangair

Sangair is a company developing an supportive medical device for treatment of sepsis. The benefits are multifunctional, but amongst other can this treatment kill bacteria present in blood without effecting other human cells negatively.

The technology is in product development phase but has a great potential to be a complementary treatment to today's SOC (Standard Operation of Care), which basically is the use of antibiotics.

Today the presence of antibiotic resistant bacteria is becoming more and more troublesome, and it is spreading. The need for alternative or complementary treatment methods is therefore one of the highest priorities according to WHO and EU.